Diag-Nose.io Secures $2M Seed Funding to Revolutionize Respiratory Care with AI-Driven Precision Medicine

Diag-Nose.io, Graduate of Stanford EENT Innovation, Closes Oversubscribed $2M Seed Round to Transform Respiratory Care with AI-Driven Precision Medicine

Enter your email to get Benzinga's ultimate morning update: The PreMarket Activity Newsletter MENLO PARK, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- A groundbreaking precision medicine system developed by biotech trailblazer Diag-Nose.io is set to transform the management of chronic respiratory diseases worldwide after closing its seed round this week. Diag-Nose.io founding team at the Stanford EENT Innovation Program A graduate of Stanford University's EENT Innovation Biodesign program in 2019, Diag-Nose.io is pioneering advancements in respiratory healthcare by focusing on the "unified airway": the biological relationship between the lungs and nasal passages. Traditional diagnostic methods for chronic respiratory conditions - such as asthma chronic obstructive pulmonary disorder (COPD) and chronic sinusitis - rely on limited measurement tools and subjective assessments. These flawed processes currently result in treatment failure for more than 30% of patients, costing hundreds of millions of dollars per year. Using machine learning (artificial intelligence) and protein signatures, Diag-Nose.io's RhinoMAP™ aims to remove the guesswork, enabling providers to match treatments to a patient's unique biological profile, or "endotype." Diag-Nose.io's approach involves collecting nasal samples using the ABEL Microsampler™, its patented nasal liquid biopsy device, followed by advanced analysis through the AI-powered RhinoMAP™ platform. The system provides insights into disease progression, therapeutic responsiveness, and triage capabilities. RhinoMAP platform "This funding allows us to delve deeper into the unexplored biology of respiratory diseases and unlock novel therapeutic pathways," said Dr. Josie Xu, Co-Founder of Diag-Nose.io and former otolaryngology and sleep apnea surgery fellow at University of Southern California Keck School of Medicine. "By combining innovative nasal liquid biopsy techniques with proteomics and AI-driven analysis, we aim not only to enhance the adoption of current treatments but also to pave the way for future breakthroughs in areas such as sleep disorders and beyond." The oversubscribed $2 million round was led by Breakthrough Victoria, with additional investments from Radar Ventures, a syndicate of physicians from Specialty Physician Associates (SPA), biotech angel investors Carl Stubbings, Stephen Ho, and Richard Lipscombe, as well as physicians affiliated with leading U.S. hospitals. Carl Stubbings will join Diag-Nose.io's board as Chairperson. "I have closely and proudly followed Diag-Nose.io's journey since they graduated from the Stanford EENT Innovation program in 2019. The team has not only demonstrated impressive scientific progress despite the pandemic, but they have also grown increasingly ambitious." said Professor Robson Capasso, Chief of Sleep Surgery, Professor of Otolaryngology and Head and Neck Surgery, and Associate Dean of Research at Stanford University School of Medicine. "It makes them well-positioned to tackle one of the burning problems in respiratory care right now; matching patients to the right biologic therapy." Diag-Nose.io plans to launch a series of clinical studies across the United States in 2025 to further validate its technology and invites interested academic and industry partners to collaborate in driving forward this revolutionary approach to respiratory care. MEDIA CONTACT For any questions in relation to this release or to discuss interviews, please contact: Nicole Papoutsis media@diag-nose.io About Diag-Nose.io Diag-Nose.io, founded in 2020, is a biotechnology company focused on translating the complexities of the unified airway into precision diagnostic and drug discovery solutions. Their precision medicine technology combines advanced proteomics, computational biology, and AI (machine learning) to create a scalable respiratory biology model. This innovation aims to help clinicians prescribe the right treatments faster and enable researchers to accelerate the development of new therapies. The company's flagship platform, RhinoMAP™, leverages proteomic data to predict respiratory disease activity, monitor therapy response and predict treatment efficacy in advance, with an initial focus on anti-Th2 biologics. website: https://diag-nose.io/ Disclaimer: The RhinoMAP platform, ABEL microsampler™, RhinoMAP™ and any associated technologies or products developed by Diag-Nose.io have not been evaluated by the U.S. Food and Drug Administration (FDA) and are not currently approved for diagnostic or therapeutic use. This press release is for informational purposes only and should not be interpreted as medical advice. Consult a qualified healthcare professional for medical guidance. This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction. Any securities described in this announcement have not been, and will not be, registered under the US Securities Act of 1933 and may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration of the US Securities Act and applicable US state securities laws. Photos accompanying this announcement are available at https://www.globenewswire.com/NewsRoom/AttachmentNg/df9ff174-42a7-4a7f-b1f7-23a2bc80274c https://www.globenewswire.com/NewsRoom/AttachmentNg/0f45d27e-6518-4a11-9185-b3182139249f Market News and Data brought to you by Benzinga APIs

Diag-Nose.io Expands to Bethlehem, PA, Following Oversubscribed $2M Seed Round Funding to Revolutionize Respiratory Diagnostics

Enter your email to get Benzinga's ultimate morning update: The PreMarket Activity Newsletter BETHLEHEM, Pa., Jan. 30, 2025 (GLOBE NEWSWIRE) -- A groundbreaking precision medicine system developed by biotech trailblazer Diag-Nose.io hopes to transform the management of chronic respiratory diseases worldwide after closing its seed round this week. Dr. David Yen, Co-founder and Chief Medical Officer of Diag-Nose.io A graduate of Stanford University's prestigious EENT Innovation Biodesign program in 2019, Diag-Nose.io is redefining respiratory healthcare through its innovative focus on the "unified airway," emphasizing the biological interplay between the lungs and nasal passages. Traditional diagnostic methods for chronic respiratory conditions - such as asthma and chronic obstructive pulmonary disorder (COPD) and chronic sinusitis - rely on limited measurement tools and subjective assessments. This approach contributes to treatment failure in over 30% of patients, incurring significant costs and delaying effective care. Diag-Nose.io's revolutionary RhinoMAP™ platform combines machine learning (AI) with advanced proteomics to enable precision-matched treatments based on each patient's unique biological profile, or "endotype." ABEL Microsampler™ The system leverages patented nasal liquid biopsy technology, the ABEL Microsampler™, to collect nasal fluid samples for comprehensive biomarker analysis. These insights intend to guide care by identifying disease progression, therapeutic responsiveness, and optimal treatment pathways. "This funding allows us to advance the RhinoMAP™ platform and the ABEL Microsampler™, ensuring our patients receive biologics or other therapies tailored to their unique biology," said Dr. David Yen, Diag-Nose.io's Co-founder and Chief Medical Officer. "Our goal is to equip physicians with tools to personalize care, improve outcomes, and reduce costs for patients globally." The oversubscribed $2 million round was led by Breakthrough Victoria, with additional investments from Radar Ventures, a syndicate of physicians from Specialty Physician Associates (SPA), biotech angel investors Carl Stubbings, Stephen Ho, and Richard Lipscombe, as well as physicians affiliated with leading U.S. hospitals. Carl Stubbings will join Diag-Nose.io's board as Chairperson. In a significant milestone, Diag-Nose.io is also expanding operations to Bethlehem, Pennsylvania, through a partnership with SPA as a dedicated clinical site. Dr. Shannon Kearney, an allergist-investor at SPA, shared her excitement about Diag-Nose.io's innovative approach: "With the RhinoMAP™ and ABEL Microsampler™, we are planning to build a biobank that will advance our understanding of treatment efficacy across a variety of devices and drugs for respiratory disease. This biology-driven precision care approach is the future of medicine." Diag-Nose.io plans to launch a series of clinical studies across the United States in 2025 to further validate its technology and invites interested partners to collaborate in driving forward this revolutionary approach to respiratory and rhinology care. MEDIA CONTACT For any questions in relation to this release or to discuss interviews, please contact: Nicole Papoutsis media@diag-nose.io About Diag-Nose.io Diag-Nose.io, founded in 2020, is a biotechnology company focused on translating the complexities of the unified airway into precision diagnostic and drug discovery solutions. Their precision medicine technology combines advanced proteomics, computational biology, and AI (machine learning) to create a scalable respiratory biology model. This innovation aims to help clinicians prescribe the right treatments faster and enable researchers to accelerate the development of new therapies. The company's flagship platform, RhinoMAP™, leverages proteomic data to predict respiratory disease activity, monitor therapy response and predict treatment efficacy in advance, with an initial focus on anti-Th2 biologics. website: https://diag-nose.io/ Disclaimer: The RhinoMAP platform, ABEL microsampler™, RhinoMAP™ and any associated technologies or products developed by Diag-Nose.io have not been evaluated by the U.S. Food and Drug Administration (FDA) and are not currently approved for diagnostic or therapeutic use. This press release is for informational purposes only and should not be interpreted as medical advice. Consult a qualified healthcare professional for medical guidance. This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction. Any securities described in this announcement have not been, and will not be, registered under the US Securities Act of 1933 and may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration of the US Securities Act and applicable US state securities laws. Photos accompanying this announcement are available at https://www.globenewswire.com/NewsRoom/AttachmentNg/3cc6f99b-ad05-44f6-937e-412040f04321 https://www.globenewswire.com/NewsRoom/AttachmentNg/586ab175-7634-47c1-8b31-45018e0f18c8 Market News and Data brought to you by Benzinga APIs

Diag-Nose.io Opens Houston Office following oversubscribed $2M Seed Round to Measure Respiratory Treatment Success Using Proteomics & AI

HOUSTON, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Diag-Nose.io, a cutting-edge biotech company pioneering precision medicine for respiratory disorders, has announced the opening of its new office in Houston, Texas, following the successful close of its oversubscribed $2 million seed round. This fundraise marks a significant step forward in the company's mission to transform respiratory care using advanced proteomics and artificial intelligence. Dr. Brian Wang, Co-founder and Co-Chief Scientific Officer of Diag-Nose.io A graduate of Stanford University's prestigious EENT Innovation Biodesign program in 2019, Diag-Nose.io is redefining respiratory healthcare through its innovative focus on the "unified airway," emphasizing the biological interplay between the lungs and nasal passages. Traditional diagnostic methods for chronic respiratory conditions - such as asthma and chronic obstructive pulmonary disorder (COPD) and chronic sinusitis - rely on limited measurement tools and subjective assessments. These methods fail more than 30% of the time, leading to ineffective treatments, high costs, and unnecessary patient suffering. Nasal liquid biopsies processing Diag-Nose.io's groundbreaking RhinoMAP™ platform tackles these challenges by integrating machine learning, a type of artificial intelligence with protein signatures to evaluate treatment efficacy and support a range of clinical applications tailored to a patient's unique biological profile. Utilizing the company's patented ABEL Microsampler™, nasal fluid samples are collected for biomarker analysis, offering actionable insights into disease progression, therapeutic responsiveness, and individualized treatment strategies. "For years, ENT treatments have lacked objective tools to measure success, relying heavily on subjective patient-reported outcomes," said Dr. Brian Wang, Diag-Nose.io's Co-founder and Co-Chief Scientific Officer. "With RhinoMAP™, we aim to introduce biological benchmarks that give clinicians clear, data-driven insights into treatment effectiveness, enabling more confident and personalized care decisions." The oversubscribed $2 million round was led by Breakthrough Victoria, with additional investments from Radar Ventures, a syndicate of physicians from Specialty Physician Associates (SPA), biotech angel investors Carl Stubbings, Stephen Ho, and Richard Lipscombe, as well as physicians affiliated with leading U.S. hospitals. Carl Stubbings will join Diag-Nose.io's board as Chairperson. In a significant milestone, Diag-Nose.io's new Houston office will focus on fostering partnerships with local health systems and advancing clinical research efforts. "With the Texas Medical Center at our doorstep and a multitude of world-class hospitals, Houston offers a unique ecosystem of healthcare innovation and collaboration," said Dr. Karen Bednarski, a physician-investor into the round. "Diag-Nose.io is perfectly positioned to provide ENT specialists with the objective tools they need to measure treatment success and improve patient outcomes." Diag-Nose.io plans to launch a series of clinical studies across the United States in 2025 to further validate its technology and invites interested partners based in Houston to collaborate in driving forward this revolutionary approach to respiratory and rhinology care. MEDIA CONTACT For any questions in relation to this release or to discuss interviews, please contact: Nicole Papoutsis media@diag-nose.io About Diag-Nose.io Diag-Nose.io, founded in 2020, is a biotechnology company focused on translating the complexities of the unified airway into precision diagnostic and drug discovery solutions. Their precision medicine technology combines advanced proteomics, computational biology, and AI (machine learning) to create a scalable respiratory biology model. This innovation aims to help clinicians prescribe the right treatments faster and enable researchers to accelerate the development of new therapies. The company's flagship platform, RhinoMAP™, leverages proteomic data to predict respiratory disease activity, monitor therapy response and predict treatment efficacy in advance, with an initial focus on anti-Th2 biologics. website: https://diag-nose.io/ Disclaimer: The RhinoMAP platform, ABEL microsampler™, RhinoMAP™ and any associated technologies or products developed by Diag-Nose.io have not been evaluated by the U.S. Food and Drug Administration (FDA) and are not currently approved for diagnostic or therapeutic use. This press release is for informational purposes only and should not be interpreted as medical advice. Consult a qualified healthcare professional for medical guidance. This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction. Any securities described in this announcement have not been, and will not be, registered under the US Securities Act of 1933 and may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration of the US Securities Act and applicable US state securities laws. Photos accompanying this announcement are available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c2c47357-2fd5-4786-b386-7c5c40c8e7fb https://www.globenewswire.com/NewsRoom/AttachmentNg/23ecec37-4eb8-4d25-b9fb-bbccc17f5192 Market News and Data brought to you by Benzinga APIs